"The US Food and Drug Administration (FDA) today approved asfotase alfa (Strensiq, Alexion Pharmaceuticals) as the first-ever therapy for patients who develop hypophosphatasia, a rare metabolic bone disorder, in childhood.
(Generic versions may still be available.)
Larodopa is indicated in the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication, and manganese intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis.
DOSAGE AND ADMINISTRATION
The optimal daily dose of Larodopa, i.e., the dose producing maximal improvement with tolerated side effects, must be determined and carefully titrated for each individual patient. The usual initial dosage is 0.5 g to 1 g daily, divided into two or more doses with food.
The total daily dosage is then increased gradually in increments not more than 0.75 g every 3 to 7 days as tolerated. The usual optimal therapeutic dosage should not exceed 8 g. The exceptional patient may carefully be given more than 8 g as required. In some patients, a significant therapeutic response may not be obtained until 6 months of treatment.
In the event general anesthesia is required, Larodopa therapy may be continued as long as the patient is able to take fluids and medication by mouth. If therapy is temporarily interrupted, the usual daily dosage may be administered as soon as the patient is able to take oral medication. Whenever therapy has been interrupted for longer periods, dosage should again be adjusted gradually; however, in many cases the patient can be rapidly titrated to his/her previous therapeutic dosage.
Tablets, pink, scored, each containing levodopa 0.1 g (NDC 0004-0072-01), 0.25 g (NDC 0004-0057-01) or 0.5 g (NDC 0004-0056-01)-bottles of 100.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/8/2004
Additional Dopar Information
- Dopar Drug Interactions Center: levodopa oral
- Dopar Side Effects Center
- Dopar FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.